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The steady, long-term decline in stomach cancer incidence and
mortality has seen its relative frequency in England and Wales fall
from 5% of all malignant neoplasms in the 1970s to 2.3% by 2002
(Coleman et al, 1993; Cooper et al, 2005). It is now only the sixth
most common cancer in men and the tenth most common in
women. The decline in incidence is probably related to changes in
diet and nutrition, improved preservation of food and a reduction
in the prevalence of Helicobacter pylori infection and in tobacco
smoking (Parkin, 2001). Incidence is higher in men (sex ratio
about 2.5 to 1), in the north of England, and in more deprived
socioeconomic groups (Coleman et al, 1999). In the late 1990s,
incidence was still 1.35 times higher in the most deprived
socioeconomic group than in the most affluent, but this ratio
was lower than in the early 1990s (1.41), because incidence fell by
about 9% in the most deprived group over this decade, slightly
faster than in the most affluent groups (Figure 1).
We analysed data for 112367 adults registered with cancer of the
stomach in England and Wales during the period 1986–1999,
approximately 81% of the 139154 eligible for analysis. The vital
status for 1.6% of eligible patients was unknown on 5 November
2002, and they were excluded from analysis. Most of the other
exclusions were for a recorded survival time of zero (date of diagnosis
same as date of death; 14.2% of cases): some of these patients did die
on the day of diagnosis, but most were registered solely from a death
certificate, and their survival time was unknown. The two groups
could not be distinguished in these data. As such patients may have
shorter-than-average survival (Berrino et al, 1995), the potential
impact on trends and inequalities in survival needs to be considered.
The percentage of eligible patients excluded with zero recorded
survival fell from 14% for those registered in 1990 to 9% for 1999, but
this trend was similar in all deprivation groups, and any impact on
trends in the deprivation gap in survival is likely to have been small.
Patients for whom stomach cancer was not the first primary
malignancy (3%) were also excluded.
The proportion of stomach cancers specified as arising in the
cardia rose from 18% during 1991–1994 (ICD-9 151.0) to 24%
during 1995–1999 (ICD-10 C16.0). This shift in the sub-site
distribution appears more likely to be real than an artefact due to
more specific pathological reporting, even though the proportion
with unspecified sub-site fell from 60 to 52%. This is because the
proportion of gastric tumours arising in the cardia has been rising
steadily from the early 1970s (6%) to the late 1980s (15%)
(Coleman et al, 1999). The proportion of cancers specified as
adenocarcinoma rose from 60 to 72% during the 1990s in these
data, and an increase in the incidence of adenocarcinomas at the
oesophagogastric junction has been reported several times (Powell
and McConkey, 1990; Newnham et al, 2003). The proportion of
cancers at other sub-sites of the stomach was stable during the 1990s:
fundus (1.5%), body (3%), antrum (6%), pylorus (2%), lesser
curvature (6–7%) and greater curvature (2–3%). The shift towards
more cardiac tumours may affect overall survival, because proximal
tumours of the stomach tend to be more difficult to remove.
SURVIVAL TRENDS
Survival has been increasing steadily and significantly. One-year
survival in men rose from 26.6% for those diagnosed during 1986–
1999 to 33.5% for those diagnosed during 1996–1999 (Figure 2).
The fitted, deprivation-adjusted average increase of 4.7% every 5
years was statistically significant (Table 1). The increase was
similar in women, from 26.3 to 32.1% (þ4.2% every 5 years). The
increase in 5-year survival was less marked, but still statistically
significant: it rose to 12.9% for men diagnosed at the end of the
1990s (þ2.0% every 5 years) and 14.0% for women (þ1.7% every
5 years). Ten-year survival for those diagnosed during 1991–1995
was 9–10%, not much less than the 5-year survival rate, suggesting
that most of the excess mortality in stomach cancer patients occurs
in the first 5 years.
Short-term predictions of survival for patients diagnosed during
2000–2001, using hybrid analysis (Brenner and Rachet, 2004),
suggest that 1-year survival will remain around 33–34%, with a
small continuing increase to around 11–14% in survival at 5 or
more years after diagnosis (Table 1).
DEPRIVATION
For men, short-term survival is significantly worse among the
most deprived groups (Table 2, Figure 3). The deprivation gap
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www.bjcancer.comwidened from  2.1% for those diagnosed during 1986–1990 to
 4.8% for those diagnosed during 1996–1999, although the
average widening of the gap ( 1.3% every 5 years) was not itself
statistically significant. The deprivation gap in 5-year survival was
less marked. Hybrid analysis suggests that the deprivation gap in
1-year survival for men could increase to around 8%.
No clear trend in the deprivation gap was seen for
women.
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Figure 2 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival estimated
with cohort or complete approach (1986–1990, 1991–1995, 1996–1999)
or hybrid approach (2000–2001) (see Rachet et al, 2008).
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 26.6 (26.1, 27.2) 29.5 (28.9, 30.1) 33.5 (32.8, 34.1) 4.7** (3.3, 6.0) 33.8 (32.8, 34.8)
Women 26.3 (25.6, 27.0) 28.6 (27.9, 29.4) 32.1 (31.2, 33.0) 4.2** (2.4, 5.9) 32.6 (31.3, 34.0)
5 years Men 10.1 (9.7, 10.5) 10.6 (10.2, 11.1) 12.9 (12.3, 13.5) 2.0** (0.9, 3.1) 13.2 (12.5, 14.0)
Women 11.1 (10.6, 11.7) 11.6 (11.1, 12.2) 14.0 (13.2, 14.9) 1.7* (0.3, 3.2) 14.3 (13.2, 15.4)
10 years Men 8.4 (7.9, 8.8) 8.9 (8.4, 9.4) 1.0 ( 0.7, 2.8) 11.0 (10.2, 11.9)
Women 9.4 (8.8, 10.0) 9.9 (9.2, 10.6) 3.2* (0.7, 5.7) 12.1 (11.0, 13.2)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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Figure 1 Trends in the age-standardised incidence of stomach cancer in
adults aged 15–99 years, by sex and deprivation group: England and Wales,
1986–1999.
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The significant improvement in stomach cancer survival in England
and Wales since 1990 continues the trend observed since the early
1970s. One-year survival improved more rapidly in the 1990s (4–5%
every 5 years) than in the 1970s and 1980s (2% every 5 years),
whereas improvements in longer-term survival have slowed down.
Gains in 5-year survival for patients diagnosed in the 1990s (2% every
5 years) were notably smaller than in the two previous decades (4%
every 5 years) (Coleman et al, 1999). This pattern probably reflects
recent improvements in perioperative mortality (Berrino et al, 1999;
Msika et al, 2000). The widening of the deprivation gap in men could
suggest that men in the most deprived group have not benefited from
this reduction in operative mortality.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  2.1* ( 3.8,  0.5)  2.2* ( 3.9,  0.5)  4.8** ( 6.9,  2.8)  1.3 ( 2.6, 0.1)  7.9** ( 10.8,  4.9)
Women 0.4 ( 1.8, 2.5)  3.0* ( 5.3,  0.7)  1.6 ( 4.4, 1.2)  1.3 ( 3.1, 0.5)  1.7 ( 5.8, 2.3)
5 years Men 0.3 ( 0.9, 1.6) 0.3 ( 0.9, 1.6)  1.7 ( 3.6, 0.1)  0.8 ( 1.9, 0.3)  2.3* ( 4.7, 0.0)
Women 1.3 ( 0.4, 2.9)  2.0* ( 3.8,  0.2) 1.7 ( 0.9, 4.3)  0.5 ( 2.0, 1.1) 1.7 ( 1.3, 4.7)
10 years Men 0.8 ( 0.5, 2.0) 0.1 ( 1.3, 1.5)  0.7 ( 2.6, 1.2)  2.0 ( 4.5, 0.5)
Women 1.4 ( 0.4, 3.1)  1.8 ( 3.9, 0.3)  3.2* ( 5.8,  0.5) 0.8 ( 2.3, 4.0)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po 0.01.
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Figure 3 Trends in the deprivation gap in 5-year relative survival (%) by sex and calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
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